ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

DNLI vs ADMA // FORWARD P/E MULTIPLE

Denali Therapeutics Inc. (NASDAQ) VS. ADMA Biologics Inc (NASDAQ) • 15-METRIC TALLY: DNLI 1 — ADMA 5
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DNLI VS. ADMA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC DNLI ADMA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 57.40% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 32.90% -67.90 ADMA /roic <GO>
EV/EBITDA & P/E Valuation — 12.4x — TIE /valuation <GO>
Free Cash Flow Yield -13.67% 1.06% -14.73 ADMA /fcf-yield <GO>
Operating Margin — 37.50% — TIE /operating-margins <GO>
Net Profit Margin — 28.80% — TIE /net-margins <GO>
Revenue Growth (YoY) — 19.60% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 10.87 12.98 -2.11 ADMA /balance-sheet <GO>
Piotroski F-Score Quality 2/9 7/9 -5.00 ADMA /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 45.3 64.1 -18.80 ADMA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple ACTIVE — 15.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $3.09B $2.63B $456.4M DNLI /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR DNLI REV ADMA REV DNLI GROSS % ADMA GROSS % DNLI FCF ADMA FCF
FY 2025 $0 $510.2M — 57.4% -$422.1M $27.8M
FY 2024 $0 $426.5M — 51.5% -$363.6M $110.4M
FY 2023 $330.5M $258.2M — — -$358.0M $8.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DNLI // BETA —
ADMA // BETA —